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Among the human gynaecologic malignancies, the difficulty in
early detection of ovarian cancer usually results in a poor patient
prognosis. The incidence has been increasing, with over 5000
ovarian cancer-related deaths each year in Japan alone. Nearly
80% of ovarian malignant tumours are of the epithelial type, with
multiple genetic changes involved in their genesis and progres-
sion, including the activation of proto-oncogenes and the inactiva-
tion of tumour suppressor genes (Stanbridge, 1990). Only now are
the detailed molecular mechanisms of the development of ovarian
tumours beginning to be elucidated. 
In addition to the well-characterized tumour suppressor genes
such as RB, WT1, and p53, several newer candidate tumour
suppressor genes, including Smad4 (Hahn et al, 1996) and PTEN
(Li et al, 1997), have been identified through LOH analysis of
human tumours. Although studies from ovarian cancers have
shown that LOH occurs at some level on most chromosome arms,
deletions were most frequently observed at 6p, 13q, 17p and 17q
(Cliby et al, 1993). In several recent studies of ovarian carcinomas,
LOH at 3p was detected in 15% (Buttitta et al, 1998), 31% (Lounis
et al, 1998), and 52% of the tumours (Fullwood et al, 1999). The
FHIT gene is located at 3p14.2, close to the chromosomal region
shown to be susceptible to LOH and cytogentic abnormalities in
ovarian carcinoma (Lounis et al, 1998). The FHIT (fragile histi-
dine triad) gene is a probable tumour suppressor gene. Its 1.1-kb
mRNA transcript is encoded by 10 exons distributed over an
amazing 1 Mb of genomic DNA. FHIT encompasses the FRA3B
fragile site and the breakpoint of the t(3:8) translocation associated
with familial renal cell carcinoma (Ohta et al, 1996). 
In vitro studies show that the human Fhit protein has the proper-
ties of a diadenosine triphosphate hydrolase (Barnes et al, 1996).
The tumour-suppressor activity of Fhit may be associated with an
involvement of the Fhit/Ap3A complex in the cytokine signaling
pathways which control cell proliferation (Kisselev et al, 1998).
Overexpression of Fhit in cells with FHIT gene abnormalities or
lacking Fhit protein expression significantly inhibits cell growth in
human lung, head and neck, and colon carcinoma cells, and also
causes an induction of tumour cell apoptosis and reduction of
tumorigenicity (Ji et al, 1999; Sard et al, 1999; Morikawa et al,
2000) but not in normal bronchial epithelial cells (Ji et al, 1999)
nor in 293 T human embryonic kidney carcinoma cells (Guo and
Vishwanatha, 2000). 
A high frequency of aberrant transcripts (30–80%) of FHIT has
been reported in various human cancers. We previously reported
that 43% of cervical carcinomas showed inactivation of both FHIT
alleles (Yoshino et al, 1998), highlighting the importance of FHIT
alteration in that tumour type. We extended our studies backwards
to normal cervical epithelia and cervical intraepithelial neoplasias
and found that inactivation of FHIT alterations also occur as a later
event in the development of endometrial carcinoma (Ozaki et al,
2000). However, reports on the role of the FHIT gene in ovarian
carcinoma are scarce. Mandai et al (1998) found concomitant
expression of normal and abnormal FHIT transcripts in 39% of
carcinomas and in 83% of borderline tumours and loss of normal
FHIT transcript in 4 (8%) cases of carcinomas, all of which were
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an abnormal FHIT transcript in only 2 of 54 ovarian carcinomas.
Therefore, reports on the role of FHIT in ovarian carcinomas are
conflicting. 
In the present study, we have analysed FHIT transcription using
RT-PCR and sequencing. We have also performed Southern DNA
analysis and LOH analysis to clarify the mechanism of the aber-
rant FHIT transcripts we found. Expression levels of Fhit protein
were examined by immunohistochemical analysis. 
MATERIALS AND METHODS 
Tissue samples 
For RT-PCR, 33 samples of ovarian carcinomas (15 serous, 5
mucinous, 5 endometrioid and 8 clear cell type), 2 ovarian border-
line tumours (1 serous and 1 mucinous type) and 10 benign
adenomas (5 serous and 5 mucinous type) were obtained from
patients of the Osaka University Hospital. Surgically removed
tissues were sampled for histological diagnosis, and the remain-
ders were quick-frozen for subsequent extraction of DNA and
RNA. Surgical staging was carried out according to the tumour-
node-metastasis (TNM) classification system of malignant
tumours defined by the International Union Against Cancer (Sobin
and Wittekind, 1997). Patient age ranged from 16 to 80 years
(mean: 49 years); surgical staging ranged from Ia to IV in these
ovarian carcinomas. For immunohistochemistry, a new series was
added to the above samples, making a total of 44 ovarian carci-
nomas, 19 borderline tumours, and 16 benign adenomas. These
samples were obtained from the Osaka University Hospital and the
Osaka Rosai Hospital. 
RNA extraction, reverse transcription-polymerase
chain reaction (RT-PCR) 
Total RNA was extracted from frozen tissues using the RNAzol B
kit (Tel TEST, Friendswood, TX) according to the manufacturer’s
instructions. For cDNA synthesis, 1 mg of total RNA was reverse
transcribed in a 30 ml volume of 1X first strand buffer, 10 mM
DTT, 500 mM dNTPs and 0.3 mg ml–1 of random hexamers. The
samples were first denatured for 10 min at 70°C, annealed with
random hexamers at 26°C for 10 min and then 10 units of MoMLV
reverse transcriptase (Life Technologies, Gaithersburg, MD) were
added. Samples were incubated at 37°C for 60 min. The reaction
was stopped by inactivating the enzyme at 70°C for 15 min. 
1 ml of this cDNA was used for the first round of PCR amp-
lification in a volume of 25 ml containing 0.8 mM of primers 
5U2 (5¢-CATCCTGGAAGCTTTGAAGCTCA-3¢) and 3D2 (5¢-
TCACTGGTTGAAGAATACAGG-3¢), as published by Ohta et al
(1996), 50 mM of each dNTP, 1X PCR buffer, and 1.25 units of
ExTaq Polymerase (Takara Shuzo, Kyoto, Japan). The PCR
consisted of an initial denaturation at 94°C for 2 min and 5 cycles
of 30 s at 94°C, 3 min at 68°C, 5 cycles of 30 s at 94°C, 3 min at
66°C, 20 cycles of 20 s at 94°C, 3 min at 64°C, using a PCR
Thermal Cycler (Perkin Elmer Cetus, Foster City, CA). The ampli-
fied product was diluted 10-fold with TE buffer (10 mM Tris-
HC1, 1 mM EDTA), and then 1 ml of the diluted reaction product
was subjected to a second round of PCR amplification using the
nested primers 5U1 (5¢-TCCGTAGTGCTATCTACATC-3¢) and
3D1 (5¢-CATGCTGATTCAGTTCCTCTTGG-3¢), as published by
Ohta et al (1996), under the conditions of an initial denaturation at
94°C for 2 min and 25 cycles of 30 s at 94°C, 30 s at 60°C, 1 min
at 72°C. For control of RT-PCR, a 319-bp fragment of b-actin
cDNA was also amplified using primers previously described
(Fuqua et al, 1990). One cycle for the b-actin fragment consisted
of 1 min each at 94°C, 50°C and 72°C. A total 30 cycles of PCR
amplification was performed. 
cDNA sequencing 
The PCR products were electrophoresed in a 1.5% agarose gel and
visualized by ethidium bromide staining. DNA was purified from
excised bands using a Gene Clean Kit (Bio 101, Vista, CA).
The products were sequenced using a Dye-Terminator Cycle
Sequencing Ready Reaction Kit (Perkin-Elmer) and run on an
automatic DNA sequencer (Applied Biosystems Model 310
Genetic Analyzer). 
Detection of allelic loss within the FHIT gene 
For analysis of allelic loss within the FHIT gene, DNA was
extracted from the tumour and normal tissue and purified as previ-
ously described (Enomoto et al, 1991). Allelic loss was detected
using amplification of D3S1300 and D3S4103 microsatellite
markers, both of which are located within intron 5 of the FHIT
gene. Primer sequences used in this study were obtained from
the Genome Database, (5¢-AGCTCACATTCTAGTCAGCCT-3¢
[forward] and 5¢-GCCAATTCCCCAGATG-3¢ [reverse] for
D3S1300, 5¢-TTCTACTGCAATCCAGCCTGG-3¢ [forward] and
5¢-GCCTTGGGTAGATTTTATACCT-3¢ [reverse] for D3S4103).
The PCR amplification reaction mix (total 10 ml) contained
genomic DNA (0.1 mg), dNTPs (50 mM), [32P]-end-labelled
reverse primer and unlabelled forward primer (1 mM each), MgCl2
(1.5 mM), Tris, pH 8.3 (10 mM), KCl (50 mM), 0.1 U Taq poly-
merase (Takara Syuzo) and 0.01% gelatin. After initial denatura-
tion at 98°C for 5 min, a total of 28 cycles of PCR were performed
with a thermal profile of 1 min at 94°C, and 1 min at 60°C. The
PCR products were analysed by electrophoresis through an 8%
non-denaturing polyacrylamide gel. 
Southern blot analysis 
For Southern blot analysis, 10 mg of genomic DNA was digested
in a 20 ml reaction mix containing 1X restriction buffer and 80
units of restriction enzyme (Hind III; Takara, Japan). Digested
DNA was electrophoresed on 0.8% agarose gel and transferred to
a Hybond N membrane (Amersham Life Science, Inc, Arlington
Heights, IL) according to the manufacturer’s instructions. A 707-
bp cDNA probe spanning exons 3 to 10 of the gene was generated
by RT-PCR and was labelled with [a-32P] dCTP using a Prime-It II
Kit (Stratagene, La Jolla, CA). Hybridization was performed at
65°C in 7 ml of Quick Hyb (Stratagene, La, Jolla, CA) for 2 hours.
Hybridized membranes were washed in 2 ´ SSC, 0.1% SDS
for 20 min at room temperature, and in 0.2 ´ SSC, 0.1% SDS for
20 min at 65°C, and subjected to autoradiography. 
Immunohistochemical analysis of Fhit protein
expression 
Formalin-fixed, paraffin-embedded tissues were sectioned at
4 mm. Antigen enhancement was performed by heating the
sections to 100°C in sodium citrate buffer (0.01 M, pH 6.0) for
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washed 3 times in phosphate buffer, treated for 10 min with 3%
hydrogen peroxide in methanol to reduce endogenous peroxidase
activity, and washed in water for 5 min. Slides were incubated with
polyvalent and universal protein blocking agent for 20 min, then
incubated with rabbit polyclonal anti-Fhit antiserum at 1: 500 dilu-
tion (Zymed Laboratories, Inc.) at 4°C for 16 h. Slides were again
washed 2 times and incubated with polyvalent and universal
blocking agent plus secondary antibody for 30 min. Avidin-biotin
complex was added to the slides for 30 min, and antibody localiza-
tion was detected by a 5-min incubation with 3,3¢-diaminobenzi-
dine. Slides were lightly counterstained with haematoxylin. 
Immunostaining was scored on a 3-tiered scale for both inten-
sity (grade 1: absent/weak, 2: moderate, 3: strong) and extent
(grade 1: percentage of positive cells is <10%, grade 2: 10–50%,
grade 3: >50%). The intensity and extent scores were then multi-
plied to give a composite score of 1–9 for each tumour (Greenspan
et al, 1997). Composite scores from 1 to 3 were defined as marked
reduction or absence of Fhit protein expression. Slides were scored
independently by 2 investigators (KO and TE). 
Statistics 
The significance of differences in the frequency with which muta-
tions occurred in different histological grades, histological
subtypes or surgical stages was estimated using Fisher’s exact test. 
RESULTS 
RT-PCR and cDNA sequencing of FHIT gene 
To study abnormal FHIT transcription in carcinogenesis of the
ovary, 33 ovarian carcinomas, 2 borderline tumours and 10 benign
adenomas were analysed for a 707-bp cDNA fragment encom-
passing exons 3 to 10 of the FHIT gene. FHIT cDNA was ampli-
fied by nested RT-PCR using tumour mRNA as template. A
319-bp fragment of b-actin was amplified from all the samples as
an internal control (data not shown). We successfully amplified
a normal-sized 707-bp FHIT fragment from all the borderline
tumours and benign adenomas. On the other hand, 5 ovarian carci-
nomas (cases 18, 19, 22, 25 and 27) exhibited complete loss of the
normal-sized 707-bp fragment; 2 of these (cases 22 and 27)
expressed only an abnormal-sized transcript, and the remaining 3
expressed no FHIT transcripts at all. For comparison, examples of
7 cases with the normal-sized 707-bp fragment, a single case with
the normal-sized 707-bp fragment and an abnormal-sized tran-
script, and a single case with only an abnormal-sized transcript, are
shown in Figure 1. 
Association of loss of the normal-sized 707-bp fragment with
tumour histological subtypes and surgical stages was evaluated.
Loss of the normal-sized 707-bp FHIT fragment was observed
in 5 of 15 serous carcinomas but not in any of 18 non-serous
carcinomas. Loss of the normal-sized 707-bp fragment was
observed in 1 of 12, 1 of 6, 3 of 13 and none of 2 ovarian carci-
nomas of stage I, II, III and IV, respectively. Therefore, there
was a significant association between loss of normal FHIT tran-
script and histological subtype (P = 0.01, serous vs. non-serous),
though no association was observed with surgical stages 
(P = 0.70). 
Abnormal FHIT transcripts were observed in 5 of 33 ovarian
carcinomas (cases 20, 22, 24, 27, and 32) and in 1 of 2 borderline
tumours (case 12), but not in any of 10 adenomas. Of the 6
tumours, which expressed abnormal FHIT transcript, 4 cases
(cases 12, 20, 24 and 32) also expressed a normal-sized 707-bp
fragment; however, 2 cases (cases 22 and 27) did not (Table 1).
The association of an abnormal FHIT transcript with different
histological subtypes and surgical stages was evaluated. An
abnormal  FHIT transcript was observed in 4 of 16 serous tumours
and 2 of 6 mucinous tumours, but not in any of 5 endometrioid
carcinomas or 8 clear cell carcinomas. An abnormal FHIT tran-
script was detected in 1 of 12, 1 of 6, 3 of 13 and none of 2 carci-
nomas of surgical stage I, II, III and IV, respectively. Therefore,
there was no apparent association between abnormal FHIT tran-
script and histological subtype (P = 0.38, serous vs. non-serous) or
surgical stages (P = 0.70). 
All PCR products were excised from an agarose gel and
subsequently sequenced. In case 20, the abnormal transcript
corresponding to the absence of exons 3 through 6 resulted from
a fusion of exons 2 and 7. In case 22, 2 types of aberrant tran-
scripts were revealed, loss of exons 4 to 6 and loss of exons 5
and 6, creating a junction between exons 3 and 7, and exons 4
and 7, respectively. In cases 24 and 32, the abnormal transcripts
showed a lack of exons 4 to 6, corresponding to the fusion of
exons 3 and 7 (Figure 2B). In cases 12 and 27, the abnormal
transcripts showed lack of exons 4 to 8 (Figure 2A), corre-
sponding to the fusion of exons 3 and 9. In all the abnormal tran-
scripts detected the deletions occurred at the exon-intron
boundary of a regular splice site. Sequencing analysis of
normal-sized transcripts showed no deletion or insertion in any
of the cases. 
Detection of allelic loss within the FHIT gene 
Allelic loss within intron 5 of the FHIT gene was detected by
amplification of the D3S1300 and D3S4103 microsatellite
markers (Figure 3). Allelic loss at the D3S1300 locus was found in
5/24 (21%) informative cases of carcinoma, 1/2 (50%) informative
cases of borderline tumours and 0/10 (0%) informative cases of
adenomas. Similarly, allelic loss at the D3S4103 microsatellite
marker was found in 5/25 (20%) informative cases of carcinomas
and 0/10 informative cases of adenomas. Among cases that
showed abnormal FHIT transcripts, 5 of 6 (83%) informative cases
at the D3S1300 locus and 2 of 3 (67%) informative cases at the
D3S4103 locus showed allelic loss. Among cases that showed loss
of normal-sized FHIT fragments, 2 of 5 (40%) informative cases at
the D3S1300 locus and 1 of 2 (50%) informative cases at the
D3S4103 locus showed allelic loss. 
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Figure 1 RT-PCR analysis of FHIT mRNA in ovarian carcinomas. A 707-bp
RT-PCR fragment encompassing exons 3 to 10 of the FHIT gene was
amplified as described in ‘Materials and Methods’. A 707-bp band of normal
size was observed in all cases except for case 27. In cases 20 and 32, the
amplified products consisted of 1 abnormal band and one normal-sized band.
Case 27 showed one abnormal band with no normal-sized band. 
M: molecular size marker (F X174/Hae III digest) 
Case No. M 3 2 0 6 3 21 52 73 03 54 0MSouthern blot analysis 
We carried out Southern blot hybridization analysis of genomic
DNA digested with Hind III to clarify whether the aberrant FHIT
transcripts are associated with DNA deletion or rearrangement. In
all 3 cases (cases 12, 22 and 27) which showed both an aberrant
FHIT transcript and LOH within intron 5, no structural abnor-
mality was observed compared to control normal tissue DNA
(Figure 4). This may indicate that the abnormal transcripts in these
cases are not associated with gross DNA alterations such as dele-
tion or rearrangement, but rather from altered splicing. 
Immunohistochemical analysis of Fhit protein
expression 
Expression levels of Fhit protein were analysed by immunohisto-
chemistry (Figure 5) in 44 ovarian carcinomas (19 serous 
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Table 1 Fhit alterations in ovarian tumours 
No. Age Histology Stage Fhit Protein Expression Fhit mRNA LOH 
I E C D3S1300 D3S4103 
Adenoma 
01 33 serous adenoma 3 3 9 N – – 
02 37 serous adenoma 3 3 9 N – – 
03 54 serous adenoma 3 3 9 N – – 
04 28 serous adenoma N.D. N – – 
05 61 serous adenoma N.D. N – – 
06 44 mucinous adenoma 3 3 9 N – – 
07 52 mucinous adenoma 2 3 6 N – – 
08 63 mucinous adenoma N.D. N – N.I. 
09 42 mucinous adenoma N.D. N – – 
10 28 mucinous adenoma N.D. N – – 
<Borderline tumour>
11 51 serous Ic 3 3 9 N – N.D. 
12 23 mucinous Ia 2 2 4 N/A Del. Exon 4–8 + N.I. 
<Carcinoma >
13 46 serous G1 Ic 3 3 9 N N.I. – 
14 53 serous G1 IIb N.D. N – – 
15 42 serous G1 IIIc N.D. N – – 
16 50 serous G1 IIIc 3 2 6 N – – 
17 43 serous G1 IV 3 3 9 N N.D. + 
18 55 serous G2 IIb 1 2 2 N.E. – – 
19 60 serous G2 IIIc 1 1 1 N.E. – – 
20 37 serous G2 IIIc 2 3 6 N/A Del. Exon 3–6 + + 
21 60 serous G2 IV N.D. N – N.D. 
22 55 serous G3 Ic 1 1 1 A1/A2 Del. Exon 4–6 / Del. Exon 5–6 + N.I. 
23 50 serous G3 IIc 2 3 6 N –  – 
24 46 serous G3 IIc 2 2 4 N/A Del. Exon 4–6 – – 
25 45 serous G3 IIIc 1 1 1 N.E. – – 
26 63 serous G3 IIIc 3 3 9 N – – 
27 70 serous G3 IIIc 1 2 2 A Del. Exon 4–8 + + 
28 80 mucinous G1 Ia 3 3 9 N – – 
29 16 mucinous G1 Ia 3 3 9 N – N.D. 
30 55 mucinous G1 Ic N.D. N – N.I. 
31 45 mucinous G1 Ic 3 3 9 N N.D. + 
32 31 mucinous G1 IIIc 3 3 9 N/A Del. Exon 4–6 + N.I. 
33 39 endometrioid G1 IIIc N.D. N – – 
34 62 endometrioid G1 IIIc 3 3 9 N – – 
35 58 endometrioid G2 Ia 3 3 9 N N.D. + 
36 43 endometrioid G2 Ib 3 3 9 N + N.D. 
37 49 endometrioid G2 IIIc 3 3 9 N N.D. – 
38 59 clear cell Ia 3 3 9 N – – 
39 72 clear cell Ic 3 3 9 N – – 
40 31 clear cell Ic 3 3 9 N – – 
41 48 clear cell Ic 3 3 9 N N.I. – 
42 59 clear cell IIc 3 3 9 N – N.D. 
43 47 clear cell IIb 3 3 9 N N.D. – 
44 56 clear cell IIIc 3 2 6 N N.D. – 
45 58 clear cell IIIc 3 3 9 N N.I. N.D. 
N.D.: not done, N: normal-sized band, A: aberrant-sized band. N.E.: not expressed, Del: deletion, N.I.: not informative, +: LOH positive, –: no LOH. I: Intensity of
immunohistochemical staining: 1, absent/weak; 2, moderate; 3, strong. E: Extent of immunohistochemical staining (percentage of positive cells): 1, <10%; 2,
10–50%; 3, >50%. C: Composite score: Intensity times Extent. adenocarcinomas, 8 mucinous adenocarcinomas, 8 endometrioid
adenocarcinomas and 9 clear cell carcinomas), 19 borderline
tumours (8 serous, 11 mucinous) and 16 benign adenomas (8
serous adenomas, 8 mucinous adenomas). All borderline tumours
and benign adenomas showed positive staining (composite score =
6–9) in the cytoplasm of epithelial components, whereas stromal
tissues were negative for staining. In carcinomas, impaired expres-
sion of Fhit protein (composite score equal to or less than 3) was
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Case No. 32
Case No. 27
A
B
Exon 3 Exon 9
30 40
Exon 3 Exon 7
30 40
Figure 2 Sequence of the abnormal-sized transcripts observed in ovarian
carcinomas. Arrows indicate the junction between exon 3 and 9 in case 27
(A) and exon 3 and 7 in case 32 (B) 
Case No.
N          T
20
N          T
27
Figure 3 LOH analysis of the D3S1300 and D3S4103 within the FHIT
gene. Arrows indicate the allelic losses in cases 20 (D3S1300) and 27
(D3S4103). T: tumour, N: matched normal tissue 
Case No.
N          T
22
N          T
12
N          T
27
23k-
9.4k-
6.5k-
4.3k-
Figure 4 Southern blot analysis of the FHIT gene in ovarian carcinomas.
Tumour (T) and matched normal DNA (N) from cases 12, 22 and 27 were
digested by Hind III and hybridized with a 707-bp FHIT cDNA probe 
Table 2 Impaired Fhit expressions in ovarian tumours 
Histology Composite score: 3ù Loss of normal Fhit
transcript
Adenoma
Serous 0/8 (0%) 0/5 (0%) 
Mucinous 0/8 (0%) 0/5 (0%) 
Borderline tumour 
Serous 0/8 (0%) 0/1 (0%) 
Mucinous 0/11 (0%) 0/1 (0%) 
Carcinoma 
Serous 6/19 (32%)* 5/15 (33%)** 
Mucinous 0/8 (0%) 0/5 (0%) 
Clear cell 0/9 (0%) 0/8 (0%) 
Endometrioid 0/8 (0%) 0/5 (0%) 
*Impaired fhit expression of serous vs non-serous P = 0.004. 
**Loss of fhit mRNA expression of serous vs non-serous P = 0.01. 
/detected in 6 of 19 (32%) serous adenocarcinomas, but not in any
of 25 non-serous carcinomas (P = 0.004, serous vs. non-serous)
(Table 2). 
Association of impaired expression of the FHIT gene product and
aberrant FHIT mRNA expression was evaluated. All 3 cases lacking
FHIT transcripts (cases 18, 19 and 25) also failed to express Fhit
protein. In addition, both cases that expressed only aberrant-sized
FHIT transcripts (cases 22 and 27) expressed no Fhit protein. In
contrast, the 4 cases that expressed an aberrant-sized FHIT transcript
together with a normal-sized FHIT transcript (cases 12, 20, 24 and
32) each expressed some detectable Fhit protein. Therefore, the
impaired expression of the Fhit protein was significantly correlated
with the loss of normal FHIT transcription (P = 0.01). In serous
carcinoma, the correlation of impaired Fhit expression with histolog-
ical grades did not quite achieve the level of statistical significance
(P = 0.26, Fisher’s exact test; G1 vs. G2 + G3 = 0/6 vs. 2/6 + 4/9). 
DISCUSSION 
It is believed that at least some fractions of ovarian carcinoma
arise from the progressive transformation of ovarian surface
epithelium through either benign tumours or borderline tumours.
Mutations involving different proto-oncogenes and tumour
suppressor genes accumulate during this process of malignant
transformation. There is growing evidence that specific genes 
are associated with each histological subtype of this tumour. 
For example, early and frequent activation of the K-ras proto-
oncogene is characteristic of the mucinous tumours and distin-
guishes them from other histological types (Enomoto et al,
1991). Also, alteration of the p53 and DCC tumour suppressor
genes is more characteristic of serous tumours than non-serous
tumours (Fujita et al, 1994; Enomoto et al, 1995). The delayed
timing of the inactivation of these genes suggests they may be
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A B C
D E F
Figure 5 Immunohistochemical detection of the Fhit protein in serous type tumours (A–D), mucinous type tumours (E–G), clear cell carcinoma (H), and
endometrioid carcinoma (I). A case of serous adenoma (case 1) (A), a case of G1 serous adenocarcinoma (case 13) (B) and a case of G2 serous adenocarcinoma
(C) showed strong positive staining (composite score = 9), whereas normal stromal tissue showed negative staining. G3 serous adenocarcinoma (case 27) (D)
showed a weak staining (composite score = 2). A case of mucinous adenoma (case 6) (E) and a case of mucinous adenocarcinoma (case 28) (G) showed positive
staining (composite score = 9), but one borderline mucinous tumour (case 12) (F) stained partially (composite score = 4). A case of clear cell carcinoma (case
40) (H) and a case of endometrioid adenocarcinoma (case 35) (I) showed positive staining (composite score = 9). Scale bar: 100 mm 
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directly associated with malignant transformation (Fujita et al,
1994; Saegusa et al, 2000). Microsatellite instability and alter-
ation of the TGF beta-type II receptor and the PTEN genes are
more characteristic of endometrioid adenocarcinomas of the
ovary (Lynch et al, 1998; Obata et al, 1998). No genetic alter-
ations occurring specifically in clear cell carcinoma have been
reported. 
The present observations indicate that impaired Fhit protein
expression occurred frequently in serous carcinomas but not in
other histological sub-types (Table 2), and that impaired Fhit
protein expression occurs in serous tumours of higher histolog-
ical grade (grade 2 or 3), but not in grade 1 serous carcinomas,
or serous tumours of low malignant potential. This suggests that
inactivation of FHIT gene by loss of expression may play a
major role in malignant transformation of the serous tumours
but may not be as involved in tumours of other histological
subtypes. 
We show that impaired Fhit protein expression is more sig-
nificantly correlated with the loss of the normal-sized FHIT tran-
script than with the presence of abnormal-sized FHIT transcripts.
Although the 6 tumours with abnormal-sized transcripts lacked a
variable number of exons, it is noteworthy that each had deletions
that included exon 5, where the authentic translation-initiation
methionine codon is located. The abnormal-sized transcripts are
thus unlikely to encode full length normally functioning Fhit
proteins. 
Aberrant transcripts of the FHIT gene have been reported in a
variety of human cancers, including lung, colon, oesophageal,
breast, head and neck, cervical and endometrial carcinomas. These
aberrant transcripts are not always associated with the presence
of genomic deletions within the FHIT locus. Mao et al (1996)
reported LOH of the FHIT locus in 13 of 16 head and neck cancer
cell lines. They found that only 5 of the 13 cell lines with LOH had
aberrant FHIT transcripts; the remaining 8 cases of LOH had normal
FHIT transcription. In 2 of the 3 cell lines without LOH there was
either an aberrant transcript or no transcript. Our analysis of the
Fhit locus of 3 ovarian carcinomas gave results supporting and
extending the findings of Mao et al (1996), that aberrant FHIT
transcription is not necessarily associated with DNA rearrange-
ment. 
It should be noted that, curiously, aberrant FHIT transcripts
have been frequently reported in many apparently histologically
normal tissues, such as peripheral-blood lymphocytes, skeletal
muscle and liver (Panagopoulos et al, 1997). We ourselves have
previously reported that 10 of 40 histologically normal cervical
tissues expressed aberrant FHIT transcripts together with normal
FHIT transcript. Loss of the normal-sized FHIT mRNA transcript,
and the corresponding loss of expression of Fhit protein, were
observed in cervical and endometrial carcinomas, but were not
found in normal cervical and endometrial tissue (Ozaki et al, 2000;
Yoshino et al, 2000). 
In the present study, loss of Fhit protein expression significantly
correlated with the complete loss of FHIT transcripts but not with
the presence of aberrant-sized FHIT transcripts. These observa-
tions suggest that loss of FHIT transcripts and the logically corre-
sponding loss of Fhit protein expression is the major mechanism
of inactivation of the FHIT gene in gynaecologic malignancies. In
conclusion, a considerable contribution of the loss of Fhit protein
expression in the development of specifically serous ovarian
cancer was found in the present study. 
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